The findings of improved glycemic control but some incidence of diabetic ketoacidosis are consistent with other early findings of use of SGLT2 inhibitors in type 1 diabetes.
A study involving the SGLT2 inhibitor dapagliflozin has found that adding the therapy to insulin and liraglutide is associated with improved glycemic control for patients with type 1 diabetes (T1D). Patients also lost weight.
Findings published recently in the Journal of Clinical Endocrinology and Metabolism were based on a study of 30 patients with T1D. The use of sodium glucose co-transporter 2 (SGLT2) inhibitors for T1D patients has drawn recent interest, and research in this area was featured at a session of the American Diabetes Association in June.
All the patients in the study had been taking liraglutide along with their insulin therapy for at least 6 months. They were randomized to receive either a 10 mg dose of dapagliflozin or placebo for 12 weeks.
Researchers reported a 0.66% decrease in glycated hemoglobin (A1C) in the dapagliflozin group and no significant change in the group taking placebo. Patients taking dapagliflozin lost an average of 1.9 kg, with no additional hypoglycemia.
Results also showed significant increases in the plasma concentrations of glucagon, free fatty acids, acetoacetate, and β-hydroxybutyrate in the dapagliflozin group. However, 2 patients in taking the study group developed diabetic ketoacidosis, which was reported in a study involving another SGLT2 inhibitor, canagliflozin, in T1D patients.
At the ADA session, researchers said SGLT2 inhibitors may provide a path away from the rapid fluctuations in blood glucose, which are a hallmark of T1D.
Reference
Kuhadya ND, Ghanim H, Mehta A, et al. Dapagliflozin as additional treatment to liraglutide and insulin in patients with type 1 diabetes [published online August 4, 2016]. J Clin Endocrinol Metab. 2016; http://dx.doi.org/10.1210/jc.2016-1451
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Balancing Care Access and Fragmentation for Better Outcomes in Veterans With Diabetes
April 22nd 2021The authors of a study in the April 2021 issue of The American Journal of Managed Care® discuss the possible reasons behind the link between care fragmentation and hospitalizations in veterans with diabetes, as well as potential opportunities to address disjointed care in the context of the widespread telehealth uptake seen during the COVID-19 pandemic.
Listen
What We’re Reading: ACA Perception; FDA Blood Sugar Warning; AI and Physician Burnout
February 22nd 2024More than half of US adults have a favorable view of the Affordable Care Act (ACA); smartwatches and rings that claim to measure blood sugar levels without piercing the skin could be dangerous and should be avoided; many believe artificial intelligence (AI) could be the solution to physician burnout.
Read More
Advancements in Diabetes Technology: Coverage, Challenges, and Pregnancy Considerations
February 15th 2024Expert interviews highlight advancements and challenges in diabetes care technology, including automated insulin delivery systems and continuous glucose monitors, as well as improvements in insurance coverage.
Read More